MPH Health Care AG (93M1.DE)
- Previous Close
24.00 - Open
24.10 - Bid 26.00 x --
- Ask --
- Day's Range
24.10 - 26.70 - 52 Week Range
17.80 - 35.60 - Volume
10,085 - Avg. Volume
1,000 - Market Cap (intraday)
112.172M - Beta (5Y Monthly) 1.11
- PE Ratio (TTM)
0.94 - EPS (TTM)
27.90 - Earnings Date May 28, 2025 - Jun 2, 2025
- Forward Dividend & Yield 1.20 (5.00%)
- Ex-Dividend Date Jul 19, 2024
- 1y Target Est
108.00
MPH Health Care AG, an investment company, engages in the healthcare business in Germany. The company operates Beauty, Pharma, and Real Estate segments. It offers medicalaesthetic beauty operations and treatments, as well as the operation and provision of medical infrastructures for partner companies; and pharmaceuticals and medical products in the therapeutic areas of oncology, HIV/AIDS, neurology, rheumatology, other chronic diseases, and aesthetic medicine. The company also focuses on therapies for cancer, HIV, rheumatology, and other chronic diseases. In addition, the company offers plastic and aesthetic treatments; and develops and sells pharmaceutical and medical products; and provides related services, as well as medical devices for the aesthetic surgery and specialist medical centres. In addition, it is involved in the provision of cytostatic solutions; and real estate activities. The company was formerly known as MPH Mittelständische Pharma Holding AG and changed its name to MPH Health Care AG in 2017. The company was founded in 2008 and is based in Berlin, Germany.
www.mph-ag.de2
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: 93M1.DE
View MorePerformance Overview: 93M1.DE
Trailing total returns as of 5/13/2025, which may include dividends or other distributions. Benchmark is DAX P (^GDAXI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 93M1.DE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 93M1.DE
View MoreValuation Measures
Market Cap
102.75M
Enterprise Value
95.42M
Trailing P/E
0.86
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
14.20
Price/Book (mrq)
0.32
Enterprise Value/Revenue
13.19
Enterprise Value/EBITDA
0.78
Financial Highlights
Profitability and Income Statement
Profit Margin
101.04%
Return on Assets (ttm)
25.94%
Return on Equity (ttm)
44.96%
Revenue (ttm)
118.24M
Net Income Avi to Common (ttm)
119.48M
Diluted EPS (ttm)
27.90
Balance Sheet and Cash Flow
Total Cash (mrq)
7.33M
Total Debt/Equity (mrq)
2.56%
Levered Free Cash Flow (ttm)
75.27M